No Data
No Data
Āshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to Its Board of Directors
Express News | Oppenheimer Reiterates Outperform on Entrada Therapeutics, Maintains $25 Price Target
Oppenheimer Initiates Entrada Therapeutics(TRDA.US) With Buy Rating, Announces Target Price $25
Entrada Therapeutics Insider Sold Shares Worth $440,801, According to a Recent SEC Filing
Forecast: Analysts Think Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Business Prospects Have Improved Drastically
H.C. Wainwright Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Maintains Target Price $18